Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | CMA1 | P23946 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.34 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.34 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL622103 | 1.00 | MEN1 (0.38) | MEN1KMT2AAKR1C3PTGS2NR1I2 | |
| SCHEMBL668642 | 0.79 | ALDH1A1 (0.41) | MEN1KMT2AAKR1C3PTGS2NR1I2 | |
| SCHEMBL13434047 | 0.78 | MEN1 (0.45) | MEN1KMT2AAKR1C3ALDH1A1TSHR | |
| SCHEMBL20546494 | 0.77 | MEN1 (0.44) | MEN1KMT2AAKR1C3PTGS2ALDH1A1 | |
| SCHEMBL20546495 | 0.77 | MEN1 (0.44) | MEN1KMT2AAKR1C3PTGS2ALDH1A1 | |
| SCHEMBL9178174 | 0.77 | MEN1 (0.44) | MEN1KMT2AAKR1C3PTGS2NR1I2 | |
| SCHEMBL9178170 | 0.77 | MEN1 (0.44) | MEN1KMT2AAKR1C3PTGS2NR1I2 | |
| SCHEMBL18316538 | 0.76 | AKR1C3 (0.42) | MEN1KMT2AAKR1C3PTGS2NR1I2 | |
| SCHEMBL9180013 | 0.76 | AKR1C3 (0.42) | MEN1KMT2AAKR1C3PTGS2NR1I2 | |
| SCHEMBL18316537 | 0.76 | AKR1C3 (0.42) | MEN1KMT2AAKR1C3PTGS2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20150183818-A1 | PROCESS FOR PREPARING DIASTEREOMERICALLY ENRICHED PHOSPHORAMIDATE DERIVATIVES OF NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-02 | — | — | US | disclosed |
| EP-2870169-A1 | PROCESS FOR PREPARING DIASTEREOMERICALLY ENRICHED PHOSPHORAMIDATE DERIVATIVES OF NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | Bristol-Myers Squibb Company (US) | 2015-05-13 | — | — | EP | disclosed |
| WO-2014008236-A1 | PROCESS FOR PREPARING DIASTEREOMERICALLY ENRICHED PHOSPHORAMIDATE DERIVATIVES OF NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-09 | — | — | WO | disclosed |
| WO-2013115813-A1 | WATER SOLUBLE SOLID PHASE PEPTIDE SYNTHESIS | CEM CORPORATION (US) | 2013-08-08 | — | — | WO | disclosed |
| EP-2606060-A1 | WATER SOLUBLE SOLID PHASE PEPTIDE SYNTHESIS | CEM Corporation (US) | 2013-06-26 | — | — | EP | disclosed |
| CN-103140497-A | Water soluble solid phase peptide synthesis | CEM CORP | 2013-06-05 | — | — | CN | disclosed |
| US-20120157563-A1 | WATER SOLUBLE SOLID PHASE PEPTIDE SYNTHESIS | CEM CORPORATION (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012024224-A1 | WATER SOLUBLE SOLID PHASE PEPTIDE SYNTHESIS | CEM CORPORATION (US) | 2012-02-23 | — | — | WO | disclosed |
| US-20120041173-A1 | WATER SOLUBLE SOLID PHASE PEPTIDE SYNTHESIS | CEM CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
| EP-0496836-B1 | SYNTHESIS AND USE OF AMINO ACID FLUORIDES AS PEPTIDE COUPLING REAGENTS | RES CORP TECHNOLOGIES INC (US) | 1995-06-14 | — | — | EP | disclosed |
| EP-0496836-A4 | SYNTHESIS AND USE OF AMINO ACID FLUORIDES AS PEPTIDE COUPLING REAGENTS | — | 1993-05-05 | — | — | EP | disclosed |
| EP-0496836-A1 | SYNTHESIS AND USE OF AMINO ACID FLUORIDES AS PEPTIDE COUPLING REAGENTS. | RES CORP TECHNOLOGIES INC (US) | 1992-08-05 | — | — | EP | disclosed |
| WO-1991005564-A1 | SYNTHESIS AND USE OF AMINO ACID FLUORIDES AS PEPTIDE COUPLING REAGENTS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1991-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183818-A1 | PROCESS FOR PREPARING DIASTEREOMERICALLY ENRICHED PHOSPHORAMIDATE DERIVATIVES OF NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | SAMHD1, TYMP, PNP | MEN1 954/4885KMT2A 3681/4885AKR1C3 1727/4885 |
| US-20120157563-A1 | WATER SOLUBLE SOLID PHASE PEPTIDE SYNTHESIS | SPAST, DNPEP, SSU72 | MEN1 4026/4885KMT2A 4018/4885AKR1C3 3061/4885 |
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | NUDT1, PNP, ATIC | MEN1 933/4885KMT2A 3176/4885AKR1C3 1748/4885 |
| US-20120041173-A1 | WATER SOLUBLE SOLID PHASE PEPTIDE SYNTHESIS | ADH1C, SSU72, ADH1A | MEN1 4170/4885KMT2A 4059/4885AKR1C3 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.